Abstract: Objective To screen the proteins associated with carboplatin-resistance in advanced ovarian serous adenocarcinoma tissues using proteomics approaches of isobaric tags for relative and absolute quantification(iTRAQ) to provide experimental basis for clinically individual treatment. Methods The specimens of primary phase Ⅲ ovarian serous adenocarcinoma tissues were collected and tested for the sensitivity to carboplatin using adenosine triphosphate tumor chemosensitivity assay (ATP-TCA). Then the samples from 15 carboplatin-resistant specimens and 15 carboplatin-sensitive specimens were mixed with equal weight. Protein samples subjected to enzymatic digestion of trypsin were labeled with identical iTRAQ tags respectively, and then the labeled peptides were separated and analyzed via high performance liquid chromatography (HPLC) followed by mass spectrometry (MS). Results A total of 755 differentially expressed proteins were identified. Compared with carboplatin-sensitive group, 429 proteins were significantly up-regulated (＞1.2-fold) and 326 proteins were significantly down-regulated (＜0.83-fold) in carboplatinresistant ovarian cancer tissues. Among these up-regulated proteins, 18 proteins were associated with tumor malignant behavior and chemoresistance, including Osteopontin (OPN), Clusterin (CLU), 5'-nucleotidase (CD73) and tissue inhibitor of metalloproteinases 1(TIMP1). Conclusion The differentially expressed proteins in carboplatin-resistant ovarian cancer tissues are identified by proteomic analysis using iTRAQ technology. The iTRAQ technology provides a good platform for the study of tumor proteomics.